An Introduction to Cardiovascular Disease
Cardiovascular diseases (CVDs) are the number one cause of death globally, taking an estimated 17.9 million lives each year. CVDs describe a number of conditions affecting the heart and circulation, including coronary heart disease, angina, congenital heart disease, hypertension and stroke. The huge and ever-increasing burden of CVDs on individuals and healthcare systems shows the urgent ongoing need for treatments and preventive measures.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer-reviewed articles from our journal portfolio. If you are looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Cardiovascular Disease Content
Addressing cardiorenal outcomes in CKD and T2D: What are the key considerations for daily practice?
Watch experts in endocrinology and in primary care discuss key considerations for addressing cardiorenal outcomes in patients with CKD/T2D
- Identify the epidemiological and pathophysiological drivers behind the progression of CKD
- Recognize the specific renal and cardiovascular risks associated with CKD and T2D and the therapies available to address them
- Apply the latest clinical guidelines to treating patients with CKD and T2D in daily practice
Latest guidelines, novel therapies and emerging options for managing dyslipidemias and ASCVD risk in daily practice
Watch cardiology experts discuss how the latest guidelines and treatments are applied to reduce ASCVD risk in patients with dyslipidemias
- Choose appropriate lipid goals for patients with dyslipidemias and at risk of ASCVD, considering the latest guidelines
- Formulate guideline-based and forward-thinking strategies to reduce ASCVD risk in patients with dyslipidemias using appropriate lipid- and lipoprotein-lowering therapies
- Recognize special populations of patients with dyslipidemias and apply important considerations when treating them with lipid- and lipoprotein-lowering therapies
Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy
Heart International. 2022;16(2):Online ahead of journal publication
Hypertrophic cardiomyopathy (HCM), along with its more common subgroup, hypertrophic obstructive cardiomyopathy (HOCM), is the most common monogenic cardiovascular disorder, with a prevalence of about 1 in 500,1 and a dominant inheritance pattern, thus clustering in affected families. Patients with HCM often have significant limitations to their exercise capacity, and while there are several underlying pathomechanisms for […]
Zsolt Piroth, TCT 2022: The value of post-PCI FFR and intravascular imaging for cardiovascular failure, a FAME 3 substudy
This FAME 3 substudy aimed to define the value of post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) and intravascular imaging for cardiovascular failure. In this touchCARDIO interview, we speak with Dr Zsolt Piroth (Gottsegen National Cardiovascular Institute, Budapest, Hungary) to discuss the substudy of the FAME 3 trial and the implications for clinical practice. […]
Zsolt Piroth, TCT 2022: The value of measuring post-PCI FFR in patients with coronary artery disease
The impact of post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) has been assessed in patients with coronary artery disease (CAD). In this touchCARDIO interview, we speak with Dr Zsolt Piroth (Gottsegen National Cardiovascular Institute, Budapest, Hungary) to discuss the prognostic value for measuring post-PCI FFR and intravascular imaging in CAD. Click here for part […]
Divaka Perera, ESC 2022: Percutaneous revascularisation in patients with severe ischaemic cardiomyopathy, the REVIVED trial
The REVIVED study aimed to assess whether the addition of stents when treating patients with severe ischaemic cardiomyopathy would be beneficial to patient outcomes. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the REVIVED trial, its outcomes and how they will affect the current treatment paradigm. […]
Divaka Perera, ESC 2022: The unmet needs in patients with heart failure due to ischaemic cardiomyopathy
In an ideal scenario, patients with ischaemic cardiomyopathy would receive specific treatment options beyond the general heart failure management currently in place. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the unmet needs in this population and give an evaluation of surgical and percutaneous revascularization in […]
Isla Mackenzie, ESC 2022: Allopurinol for ischaemic heart disease, the ALL-HEART study
The ALL-HEART study is the first large, randomised trial assessing allopurinol in patients with ischaemic heart disease. In this touchCARDIO interview, we speak with Professor Isla Mackenzie (University of Dundee, Dundee, Scotland) to discuss the rationale for the ALL-HEART study, its findings and the future of allopurinol in ischaemic heart disease. The abstract entitled ‘ALL-HEART […]
Ganesan Karthikeyan, ESC 2022: Rivaroxaban versus VKAs in patients with rheumatic heart disease related atrial fibrillation, the INVICTUS program
INVICTUS aimed to assess rivaroxaban compared with vitamin K antagonists (VKAs) in patients with rheumatic heart disease related atrial fibrillation. In this touchCARDIO interview, we speak with Professor Ganesan Karthikeyan (All India Institute of Medical Sciences, New Delhi, India) to discuss the INVICTUS rheumatic heart disease research program and what this means for clinical practice. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!